The lowering of the price target by Wedbush from $24 to $7 indicates a potential decrease in the short-term value of Theseus Pharmaceuticals' stock. However, the maintained Outperform rating suggests that the stock is still expected to outperform the market, which could mitigate some of the negative impact.